

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

SPECTRUM PHARMACEUTICALS, INC.        )  
and UNIVERSITY OF STRATHCLYDE,        )  
  )  
  Plaintiffs,        )  
  )  
  v.                        )  
  )  
INNOPHARMA, INC.,                        )  
  )  
  Defendant.        )

C.A. No. \_\_\_\_\_

**COMPLAINT**

Plaintiffs Spectrum Pharmaceuticals, Inc. (“Spectrum”) and University of Strathclyde (“Strathclyde”) (collectively “Plaintiffs”), by their undersigned attorneys, for their Complaint against Defendant InnoPharma, Inc. (“InnoPharma”), herein allege:

**NATURE OF THE ACTION**

1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. § 100 et seq., including 35 U.S.C. § 271(e)(2), and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202, arising from InnoPharma’s filing of an Abbreviated New Drug Application (“ANDA”) under Section 505(j) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(j), seeking U.S. Food and Drug Administration (“FDA”) approval to market levoleucovorin products, which are generic forms of Spectrum’s pharmaceutical product Fusilev<sup>®</sup>, prior to the expiration of United States Patent No. 6,500,829 (“the ‘829 patent”), which covers Fusilev<sup>®</sup>.

**THE PARTIES**

2. Spectrum is a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 11500 South Eastern Avenue, Suite

240, Henderson, Nevada 89052. Spectrum is engaged in the business of research, development, manufacture, and sale of pharmaceutical products.

3. Strathclyde, incorporated by Royal Charter of Queen Elisabeth II, is a charitable body registered in Scotland with registration number SC015263, having its principal place of business at 16 Richmond Street, Glasgow G1 1XQ, Scotland, United Kingdom.

4. On information and belief, InnoPharma is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 10 Knightsbridge Road, Piscataway, New Jersey. On information and belief, InnoPharma is in the business of making and selling generic pharmaceutical products, which it distributes in the State of Delaware and throughout the United States.

#### **JURISDICTION AND VENUE**

5. This Court has subject-matter jurisdiction over this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

6. This Court has personal jurisdiction over InnoPharma because, on information and belief, it is a Delaware corporation.

7. On information and belief, InnoPharma has purposefully conducted and continues to conduct business in this District, including by having availed itself of the rights, protections, and benefits of Delaware law, such that it should reasonably anticipate being haled into court in this District. InnoPharma has systematic and continuous contacts with the State of Delaware, by, among other things, selling pharmaceutical products to residents of Delaware, and to others with the intent that those products are marketed and distributed in Delaware, and receiving significant revenue for the sale of those products in Delaware.

8. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391(c) and 1400(b).

### **THE PATENT-IN-SUIT**

9. On December 31, 2002, the United States Patent and Trademark Office issued U.S. Patent No. 6,500,829, entitled “Substantially Pure Diastereoisomers of Tetrahydrofolate Derivatives.” At the time of its issue, the ‘829 patent was assigned to Strathclyde. Strathclyde currently holds title to the ‘829 patent. Strathclyde has exclusively licensed the ‘829 patent to Spectrum. A copy of the ‘829 patent is attached hereto as Exhibit A.

### **FUSILEV<sup>®</sup>**

10. Spectrum holds New Drug Application No. 20-140 (initially approved on March 7, 2008) (“the Fusilev<sup>®</sup> NDA”) approving Spectrum to market a levoleucovorin product as a lyophilized powder in a 50 mg dosage strength, which is marketed by Spectrum under the trade name Fusilev<sup>®</sup>.

11. On April 20, 2011, the FDA granted Spectrum’s supplemental New Drug Application (submitted on December 22, 2010) approving Spectrum to market Fusilev<sup>®</sup> in 175 mg and 250 mg dosage strengths as solutions for intravenous infusion (“the Fusilev<sup>®</sup> sNDA”).

12. The FDA approved the 175 mg and 250 mg dosage strengths to treat patients diagnosed with advanced metastatic colorectal cancer.

13. On November 7, 2011, the FDA granted Fusilev<sup>®</sup> seven years of orphan-drug exclusive approval pursuant to Section 527 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360cc) for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of advanced metastatic adenocarcinoma of the colon and rectum.

14. Pursuant to 21 U.S.C. § 355(b)(1) and attendant FDA regulations, the '829 patent is listed in the FDA publication "Approved Drug Products with Therapeutic Equivalence Evaluations" ("the Orange Book") with respect to Fusilev<sup>®</sup>.

#### **INNOPHARMA'S ANDA**

15. On information and belief, InnoPharma submitted an Abbreviated New Drug Application, ANDA No. 203576, to the FDA, pursuant to 21 U.S.C. §§ 355(j), seeking approval to market "ready to use" vials of levoleucovorin with 175 mg and 250 mg dosage strengths ("InnoPharma's ANDA"). The levoleucovorin vials described in InnoPharma's ANDA are herein referred to as "InnoPharma's Products."

16. On information and belief, InnoPharma's ANDA refers to and relies upon the Fusilev<sup>®</sup> NDA and/or the Fusilev<sup>®</sup> sNDA and contains data that, according to InnoPharma, demonstrates the bioequivalence of InnoPharma's Products and Fusilev<sup>®</sup>.

17. By filing InnoPharma's ANDA, InnoPharma has necessarily represented to the FDA that InnoPharma's Products have the same active ingredient as Fusilev<sup>®</sup>, have the same routes of administration, dosage forms, and strengths as Fusilev<sup>®</sup>, are bioequivalent to Fusilev<sup>®</sup>, and have the same or substantially the same proposed labeling as Fusilev<sup>®</sup>.

18. Spectrum received a letter from InnoPharma on or around January 23, 2012, and an attached memorandum (collectively "InnoPharma's Notification"), stating that InnoPharma had included a certification in InnoPharma's ANDA, pursuant to 21 U.S.C. §355(j)(2)(A)(vii)(IV), that the '829 patent is invalid, unenforceable, or will not be infringed by the commercial manufacture, use, or sale of InnoPharma's Products.

19. This action is being brought within forty-five days from the date that Spectrum received InnoPharma's Notification.

**COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,500,829**

20. Plaintiffs reallege and incorporate by reference the allegations of paragraphs 1-19 of this Complaint.

21. The '829 patent contains claims directed to, for example (claim 1), "A pharmaceutical composition for therapeutic use which consists essentially of a therapeutically effective amount sufficient for the treatment of human beings for methotrexate rescue or folate deficiency, of a pharmaceutically acceptable compound which is a (6S) diastereoisomer selected from the group consisting of (6S) leucovorin (5-formyl-(6S)-tetrahydrofolic acid) and pharmaceutically acceptable salts and esters of (6S) leucovorin; wherein the compound consists of a mixture of (6S) and (6R) diastereoisomers and consists of at least 92% by weight of the (6S) diastereoisomer, the balance of said compound consisting of the (6R) diastereoisomer; in combination with a pharmaceutically acceptable carrier."

22. InnoPharma has committed an act of infringement under 35 U.S.C. § 271(e)(2)(A) by submitting InnoPharma's ANDA, by which InnoPharma seeks approval from the FDA to engage in the commercial manufacture, use, offer to sell, sale, or importation of InnoPharma's Products prior to the expiration of the '829 patent.

23. InnoPharma's commercial manufacture, use, offer to sell, or sale of InnoPharma's Products within the United States, or importation of InnoPharma's Products into the United States, during the term of the '829 patent would further infringe one or more claims of the '829 patent under 35 U.S.C. §§ 271(a), (b), and/or (c).

24. InnoPharma's filing of InnoPharma's ANDA and its intention to engage in the commercial manufacture, use, offer to sell, sale, or importation of InnoPharma's Products

upon receiving FDA approval creates an actual case or controversy with respect to infringement of the '829 patent.

25. Plaintiffs are entitled to the relief provided by 35 U.S.C. § 271(e)(4), including an order of this Court that the effective date of any approval relating to InnoPharma's ANDA shall not be earlier than December 31, 2019, the current expiration date of the '829 patent, or any later expiration date to which Plaintiffs become entitled.

26. This is an exceptional case, and Plaintiffs are entitled to an award of attorneys' fees, under 35 U.S.C. § 285.

#### **PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs pray that this Court grant the following relief:

A. A declaration that by filing InnoPharma's ANDA, InnoPharma has infringed one or more claims of the '829 patent under 35 U.S.C. § 271(e)(2)(A);

B. A declaration that one or more claims of the '829 patent would be infringed by the manufacture, use, offer for sale, or sale of InnoPharma's Products within the United States, or by importation of InnoPharma's Products into the United States;

C. An Order preliminarily and permanently enjoining InnoPharma, its officers, agents, servants, and employees, and those persons in active concert or participation with any of them, from manufacturing, using, offering to sell, or selling InnoPharma's Products within the United States, or importing InnoPharma's Products into the United States, prior to the expiration of the '829 patent (including any extensions thereof);

D. An Order prohibiting InnoPharma, its officers, agents, servants, and employees, and those persons in active concert or participation with any of them, from seeking,

obtaining, or maintaining approval of InnoPharma's ANDA, prior to the expiration of the '829 patent (including any extensions thereof);

E. A declaration that the effective date of any approval of InnoPharma's ANDA under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)) shall not be earlier than the expiration date of the '829 patent (including any extensions thereof);


F. A judgment awarding Plaintiffs damages or other monetary relief if InnoPharma commercially manufactures, uses, offers to sell, or sells InnoPharma's Products within the United States, or imports InnoPharma's Products into the United States, prior to the expiration of the '829 patent (including any extensions thereof), and that any such damages or monetary relief be trebled and awarded to Plaintiffs with prejudgment interest;

G. A declaration that this is an exceptional case and a judgment awarding Plaintiffs their reasonable attorneys' fees incurred in this action pursuant to 35 U.S.C. § 285 and 271(e)(4);

H. Reasonable filing fees, costs and expenses incurred by Plaintiffs in this action; and

I. Such further and other relief as this Court deems just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

  
\_\_\_\_\_  
Jack B. Blumenfeld (#1014)  
Rodger D. Smith II (#3778)  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
(302) 658-9200  
jblumenfeld@mnat.com  
rsmith@mnat.com

*Attorneys for Spectrum Pharmaceuticals, Inc.  
and University of Strathclyde*

OF COUNSEL:

Mark H. Izraelewicz

Kevin M. Flowers

Cullen N. Pendleton

Amanda Antons

MARSHALL, GERSTEIN & BORUN LLP

233 South Wacker Drive

6300 Sears Tower

Chicago, IL 60606-6357

(312) 474-6300

March 2, 2012